Table 1.
Patient characteristics in matched analysis
| Variable | Patients with asthma | Patients with COPD | ||||||
| BF Spiromax (n=253) |
BF Turbuhaler (n=743) |
P value | SMD (%) | BF Spiromax (n=132) |
BF Turbuhaler (n=348) |
P value | SMD (%) | |
| Mean (SD) age, years | 55.9 (15.3) | 55.8 (15.1) | 0.9101 | 0.7 | 70.5 (8.8) | 70.5 (8.5) | 0.9512 | 0.2 |
| Men, n (%) | 112 (44.3) | 331 (44.5) | 0.9382 | 0.6 | 66 (50.0) | 184 (52.9) | 0.5736 | 5.7 |
| Body mass index*, n (%) | 0.4038 | 12.1 | 0.6977 | 7.4 | ||||
| <18.5 kg/m2 | 3 (1.3) | 9 (1.2) | 6 (4.7) | 11 (3.2) | ||||
| 18.5 to<25 kg/m2 | 65 (27.2) | 163 (22.5) | 46 (35.7) | 112 (32.4) | ||||
| 25 to<30 kg/m2 | 88 (36.8) | 265 (36.5) | 39 (30.2) | 120 (34.7) | ||||
| >30 kg/m2 | 83 (34.7) | 289 (39.8) | 38 (29.5) | 103 (29.8) | ||||
| Smoking status†, n (%) | 0.7393 | 5.2 | 0.5696 | 10.8 | ||||
| Non-smoker | 126 (50.8) | 397 (53.6) | 14 (10.6) | 48 (13.9) | ||||
| Current smoker | 44 (17.7) | 123 (16.6) | 36 (27.3) | 98 (28.3) | ||||
| Ex-smoker | 78 (31.5) | 220 (29.7) | 82 (62.1) | 200 (57.8) | ||||
| Cardiovascular disease, n (%) | ||||||||
| Ischaemic heart disease | 13 (5.1) | 62 (8.3) | 0.0951 | 12.8 | 22 (16.7) | 78 (22.4) | 0.1662 | 14.5 |
| Heart failure | 1 (0.4) | 8 (1.1) | 0.3225 | 8.0 | 4 (3.0) | 23 (6.6) | 0.1286 | 16.7 |
| Exacerbations, n (%) | 0.9869 | 3.6 | 0.7809 | 12.9 | ||||
| 0 | 199 (78.7) | 593 (79.8) | 54 (40.9) | 156 (44.8) | ||||
| 1 | 42 (16.6) | 120 (16.2) | 38 (28.8) | 106 (30.5) | ||||
| 2 | 7 (2.8) | 18 (2.4) | 15 (11.4) | 35 (10.1) | ||||
| 3 | 4 (1.6) | 9 (1.2) | 13 (9.8) | 28 (8.0) | ||||
| ≥4 | 1 (0.4) | 3 (0.4) | 12 (9.1) | 23 (6.6) | ||||
| No. of respiratory-related hospital admissions, n (%) | 1.0000 | 0 | 0.1460 | 2.8 | ||||
| 0 | 253 (100.0) | 743 (100.0) | 129 (97.7) | 338 (97.1) | ||||
| 1 | 0 | 0 | 1 (0.8) | 9 (2.6) | ||||
| ≥2 | 0 | 0 | 2 (1.5) | 1 (0.3) | ||||
| Uncontrolled risk domain control, n (%) | 70 (27.7) | 194 (26.1) | 0.6278 | 3.5 | 78 (59.1) | 192 (55.2) | 0.4397 | 7.9 |
| No. of antibiotic courses, n (%) | 0.8362 | 5.5 | 0.9478 | 6.4 | ||||
| 0 | 212 (83.8) | 630 (84.8) | 74 (56.1) | 198 (56.9) | ||||
| 1 | 34 (13.4) | 99 (13.3) | 37 (28.0) | 104 (29.9) | ||||
| 2 | 5 (2.0) | 12 (1.6) | 11 (8.3) | 26 (7.5) | ||||
| 3 | 1 (0.4) | 1 (0.1) | 4 (3.0) | 8 (2.3) | ||||
| ≥4 | 1 (0.4) | 1 (0.1) | 6 (4.5) | 12 (3.4) | ||||
| No. of acute OCS courses, n (%) | 0.9869 | 3.6 | 0.6813 | 14.4 | ||||
| 0 | 199 (78.7) | 593 (79.8) | 79 (59.8) | 225 (64.7) | ||||
| 1 | 42 (16.6) | 120 (16.2) | 28 (21.2) | 74 (21.3) | ||||
| 2 | 7 (2.8) | 18 (2.4) | 9 (6.8) | 20 (5.7) | ||||
| 3 | 4 (1.6) | 9 (1.2) | 7 (5.3) | 15 (4.3) | ||||
| ≥4 | 1 (0.4) | 3 (0.4) | 9 (6.8) | 14 (4.0) | ||||
| Average daily SABA dose, n (%) | 0.4055 | 4.9 | 0.3524 | 8.4 | ||||
| 0 µg /day | 64 (25.3) | 224 (30.1) | 23 (17.4) | 65 (18.7) | ||||
| >0 µg/day to ≤200 µg/day | 70 (27.7) | 196 (26.4) | 22 (16.7) | 66 (19.0) | ||||
| >200 µg/day to ≤400 µg/day | 56 (22.1) | 139 (18.7) | 32 (24.2) | 78 (22.4) | ||||
| >400 µg/day to ≤600 µg/day | 25 (9.9) | 59 (7.9) | 5 (3.8) | 29 (8.3) | ||||
| >600 µg/day | 38 (15.0) | 125 (16.8) | 50 (37.9) | 110 (31.6) | ||||
*Some missing data for this parameter: n=239 for asthma on BF Spiromax, n=726 for asthma on BF Turbuhaler; n=129 for COPD on BF Spiromax, n=346 for COPD on BF Turbuhaler.
†
Some missing data for this parameter: n=248 for asthma on BF Spiromax, n=740 for asthma on BF Turbuhaler, n=346 for COPD on BF Turbuhaler.
BF, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; OCS, oral corticosteroids; SABA, short-acting β2-agonist; SMD, standardised mean difference.